{"id":25016,"date":"2022-10-19T23:10:00","date_gmt":"2022-10-19T15:10:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25016"},"modified":"2025-02-02T23:13:48","modified_gmt":"2025-02-02T15:13:48","slug":"shanghais-hrain-biotechnology-plans-ipo-on-star-board-to-raise-rmb-2-539-billion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25016","title":{"rendered":"Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion"},"content":{"rendered":"\n

Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial public offering (IPO) of 50 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The offering is expected to raise RMB 2.539 billion (USD 352.6 million). The proceeds will be allocated towards cell therapy research and development, construction of headquarters and industrialization bases, and supplementary working capital.<\/p>\n\n\n\n

Product Pipeline and Development<\/strong>
Hrain Bio’s product pipeline consists of 11 programs involving 10 products, including chimeric antigen receptor (CAR)-T, CAR-NK, and other innovative therapies. Among these, HR001, a CD-19 targeted CAR-T therapy with priority review status, is expected to file for marketing approval next year. This pipeline underscores Hrain Bio’s commitment to advancing cutting-edge immunotherapies for cancer treatment.<\/p>\n\n\n\n

Financial Performance<\/strong>
Hrain Bio reported net losses of RMB 193 million (USD 26.7 million) in 2021 and RMB 117 million (USD 16.2 million) in the first half of 2022. Despite these losses, the company’s strategic investments in R&D and pipeline expansion position it for long-term growth in the oncology market.<\/p>\n\n\n\n

Future Outlook<\/strong>
The planned IPO on the STAR Board highlights Hrain Bio’s ambition to secure funding for its ambitious R&D initiatives and infrastructure development. With a robust pipeline of cell therapies and a focus on innovative treatments, Hrain Bio aims to solidify its position as a leader in tumor immunotherapy.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,21,77,20,2548,72],"class_list":["post-25016","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-car-t","tag-cell-therapy","tag-finance","tag-hrain-biotechnology","tag-ipo"],"yoast_head":"\nShanghai's Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial public offering (IPO) of 50 million shares on the Shanghai Stock Exchange's Sci-Tech Innovation Board (STAR). The offering is expected to raise RMB 2.539 billion (USD 352.6 million). The proceeds will be allocated towards cell therapy research and development, construction of headquarters and industrialization bases, and supplementary working capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25016\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai's Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25016\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-19T15:10:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-02T15:13:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25016#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25016\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion\",\"datePublished\":\"2022-10-19T15:10:00+00:00\",\"dateModified\":\"2025-02-02T15:13:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25016\"},\"wordCount\":239,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"CAR-T\",\"Cell-therapy\",\"Finance\",\"Hrain Biotechnology\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25016#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25016\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25016\",\"name\":\"Shanghai's Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-19T15:10:00+00:00\",\"dateModified\":\"2025-02-02T15:13:48+00:00\",\"description\":\"Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial public offering (IPO) of 50 million shares on the Shanghai Stock Exchange's Sci-Tech Innovation Board (STAR). The offering is expected to raise RMB 2.539 billion (USD 352.6 million). The proceeds will be allocated towards cell therapy research and development, construction of headquarters and industrialization bases, and supplementary working capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25016#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25016\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25016#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai's Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion - Insight, China's Pharmaceutical Industry","description":"Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial public offering (IPO) of 50 million shares on the Shanghai Stock Exchange's Sci-Tech Innovation Board (STAR). The offering is expected to raise RMB 2.539 billion (USD 352.6 million). The proceeds will be allocated towards cell therapy research and development, construction of headquarters and industrialization bases, and supplementary working capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25016","og_locale":"en_US","og_type":"article","og_title":"Shanghai's Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25016","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-19T15:10:00+00:00","article_modified_time":"2025-02-02T15:13:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25016#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25016"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion","datePublished":"2022-10-19T15:10:00+00:00","dateModified":"2025-02-02T15:13:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25016"},"wordCount":239,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","CAR-T","Cell-therapy","Finance","Hrain Biotechnology","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25016#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25016","url":"https:\/\/flcube.com\/?p=25016","name":"Shanghai's Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-19T15:10:00+00:00","dateModified":"2025-02-02T15:13:48+00:00","description":"Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial public offering (IPO) of 50 million shares on the Shanghai Stock Exchange's Sci-Tech Innovation Board (STAR). The offering is expected to raise RMB 2.539 billion (USD 352.6 million). The proceeds will be allocated towards cell therapy research and development, construction of headquarters and industrialization bases, and supplementary working capital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25016#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25016"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25016#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25016"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25016\/revisions"}],"predecessor-version":[{"id":25017,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25016\/revisions\/25017"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}